RU2002118308A - Способы получения полиморфных модификаций кларитромицина - Google Patents

Способы получения полиморфных модификаций кларитромицина

Info

Publication number
RU2002118308A
RU2002118308A RU2002118308/15A RU2002118308A RU2002118308A RU 2002118308 A RU2002118308 A RU 2002118308A RU 2002118308/15 A RU2002118308/15 A RU 2002118308/15A RU 2002118308 A RU2002118308 A RU 2002118308A RU 2002118308 A RU2002118308 A RU 2002118308A
Authority
RU
Russia
Prior art keywords
clarithromycin
water
suspending
converting
suspended
Prior art date
Application number
RU2002118308/15A
Other languages
English (en)
Russian (ru)
Inventor
Игорь ЛИФШИЦ (IL)
Игорь ЛИФШИЦ
Иль АВРУТОВ (IL)
Илья АВРУТОВ
Эди ШВАРЦ (IL)
Эди ШВАРЦ
Басем МАСАРВА (IL)
Басем МАСАРВА
Original Assignee
Тева Фамэситикл Индастрис Лтд. (Il)
Тева Фамэситикл Индастрис Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22640371&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2002118308(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Тева Фамэситикл Индастрис Лтд. (Il), Тева Фамэситикл Индастрис Лтд. filed Critical Тева Фамэситикл Индастрис Лтд. (Il)
Publication of RU2002118308A publication Critical patent/RU2002118308A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
RU2002118308/15A 2000-01-11 2000-12-15 Способы получения полиморфных модификаций кларитромицина RU2002118308A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17547700P 2000-01-11 2000-01-11
US60/175477 2000-01-11

Publications (1)

Publication Number Publication Date
RU2002118308A true RU2002118308A (ru) 2004-02-20

Family

ID=22640371

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2002118308/15A RU2002118308A (ru) 2000-01-11 2000-12-15 Способы получения полиморфных модификаций кларитромицина

Country Status (22)

Country Link
US (2) US6624292B2 (enExample)
EP (1) EP1280535B1 (enExample)
JP (1) JP2003519661A (enExample)
KR (1) KR20020071012A (enExample)
CN (1) CN1450903A (enExample)
AT (1) ATE288758T1 (enExample)
AU (2) AU2001222619C1 (enExample)
BR (1) BR0016992A (enExample)
CA (1) CA2397092A1 (enExample)
DE (1) DE60018119T2 (enExample)
DK (1) DK1280535T3 (enExample)
ES (1) ES2236023T3 (enExample)
HR (1) HRP20020572A2 (enExample)
HU (1) HUP0204252A3 (enExample)
IL (1) IL150698A0 (enExample)
IS (1) IS6463A (enExample)
PL (1) PL356645A1 (enExample)
PT (1) PT1280535E (enExample)
RU (1) RU2002118308A (enExample)
SI (1) SI1280535T1 (enExample)
WO (1) WO2001051059A1 (enExample)
ZA (1) ZA200205229B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1666991A (zh) * 1999-12-16 2005-09-14 特瓦制药工业有限公司 克拉霉素多晶型物的制备方法和新的多晶型物ⅳ
CN1450903A (zh) * 2000-01-11 2003-10-22 特瓦制药工业有限公司 克拉霉素多晶型物的制备方法
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
CA2401571A1 (en) * 2000-02-29 2001-09-07 Ilya Avrutov Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
AU6381201A (en) * 2000-03-28 2001-10-08 Biochemie Gmbh Granulated particles with masked taste
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
ES2288898T3 (es) * 2001-08-13 2008-02-01 Fondazione Salvatore Maugeri - Clinica del Lavoro e della Riabilitazione Uso de composiciones de claritromicina en la fabricacion de un medicamento para el tratamiento de la artritis deformante.
US20060083759A1 (en) * 2002-07-17 2006-04-20 Aleksander Resman Stabilization of the profile of release of active substances from a formulation
JP2006528185A (ja) 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
WO2005009368A2 (en) 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
EP1648415A4 (en) 2003-07-21 2011-11-16 Middlebrook Pharmaceuticals Inc ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION
CA2535177A1 (en) 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
CA2535398C (en) 2003-08-12 2013-11-12 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
WO2005023184A2 (en) * 2003-08-29 2005-03-17 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
AU2004273830B2 (en) 2003-09-15 2011-03-24 Shionogi, Inc. Antibiotic product, use and formulation thereof
WO2005061524A2 (en) * 2003-12-22 2005-07-07 Ranbaxy Laboratories Limited Process for the preparation of form ii clarithromycin
EP1701705A4 (en) * 2003-12-24 2007-08-08 Advancis Pharmaceutical Corp IMPROVED ABSORPTION OF DOSAGE FORMS WITH MODIFIED RELEASE
WO2005072893A1 (en) * 2004-01-28 2005-08-11 Cytimmune Sciences, Inc. Functionalized colloidal metal compositions and methods
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
US7468428B2 (en) * 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
EP1771158A4 (en) 2004-07-02 2008-03-12 Advancis Pharmaceutical Corp TABLET FOR PULSE DISTRIBUTION
CA2614412A1 (en) * 2005-07-07 2007-01-18 Elan Pharma International, Limited Nanoparticulate clarithromycin formulations
US20070122483A1 (en) * 2005-11-29 2007-05-31 Sharon Myers Fluocinolone acetonide drug substance polymorphic interconversion
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
WO2011026234A1 (en) * 2009-09-02 2011-03-10 Bernard Charles Sherman Clarithromycin extended-release tablet
AU2014348523B2 (en) 2013-11-15 2019-01-03 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2473525A1 (fr) 1980-01-11 1981-07-17 Roussel Uclaf Nouvelles oximes derivees de l'erythromycine, leur procede de preparation et leur application comme medicaments
US4331803A (en) 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
JPS60214796A (ja) 1984-04-06 1985-10-28 Taisho Pharmaceut Co Ltd ６−０−メチルエリスロマイシン類の製法
JPS61103890A (ja) 1984-10-26 1986-05-22 Taisho Pharmaceut Co Ltd ６−０−メチルエリスロマイシンａ誘導体
US4670549A (en) 1985-03-18 1987-06-02 Taisho Pharmaceutical Co., Ltd. Method for selective methylation of erythromycin a derivatives
US4640910A (en) 1985-11-12 1987-02-03 Abbott Laboratories Erythromycin A silylated compounds and method of use
US4672056A (en) 1985-11-12 1987-06-09 Abbott Laboratories Erythromycin A derivatives and method of use
KR960000434B1 (ko) 1986-12-17 1996-01-06 다이쇼 세이야꾸 가부시끼가이샤 에리스로마이신 a유도체 및 그의 제조 방법
GB8721165D0 (en) 1987-09-09 1987-10-14 Beecham Group Plc Chemical compounds
JP2751385B2 (ja) 1988-05-19 1998-05-18 大正製薬株式会社 エリスロマイシンａオキシム及びその塩の製造方法
US5440505A (en) * 1994-01-21 1995-08-08 Intel Corporation Method and circuitry for storing discrete amounts of charge in a single memory element
US5872229A (en) 1995-11-21 1999-02-16 Abbott Laboratories Process for 6-O-alkylation of erythromycin derivatives
US5756473A (en) 1995-11-21 1998-05-26 Abbott Laboratories 6-O-methyl erythromycin D and process for making
US5837829A (en) 1996-04-02 1998-11-17 Abbott Laboratories 9-oximesilyl erythromycin a derivatives
US5719272A (en) 1996-04-02 1998-02-17 Abbott Laboratories 2'-protected 3'-dimethylamine, 9-etheroxime erythromycin A derivatives
US5808017A (en) 1996-04-10 1998-09-15 Abbott Laboratories Process for preparing erythromycin A oxime
US5858986A (en) 1996-07-29 1999-01-12 Abbott Laboratories Crystal form I of clarithromycin
US5844105A (en) 1996-07-29 1998-12-01 Abbott Laboratories Preparation of crystal form II of clarithromycin
CA2261732C (en) * 1996-07-29 2001-07-24 Abbott Laboratories Preparation of crystal form ii of clarithromycin
US5945405A (en) 1997-01-17 1999-08-31 Abbott Laboratories Crystal form O of clarithromycin
US5864023A (en) 1997-02-13 1999-01-26 Abbott Laboratories 3'-N'oxide, 3'-n-dimethylamine, 9-oxime erythromycin a derivatives
US5852180A (en) 1997-11-17 1998-12-22 Abbott Laboratories Chemical synthesis of 6-O-alkyl erythromycin A
US5932710A (en) 1997-12-01 1999-08-03 Abbott Laboratories Process for preparing 6-O-alkyl-9-oxime erythromycin B
US5892008A (en) 1997-12-16 1999-04-06 Abbott Laboratories Process for the preparation of 6-O-methyl erythromycin a using 9-hydroxy erythromycin derivatives
KR100377159B1 (ko) 1998-09-09 2003-08-19 한미약품공업 주식회사 잔류 용매가 없는 클라리스로마이신의 결정형 2의 제조 방법
CN1666991A (zh) * 1999-12-16 2005-09-14 特瓦制药工业有限公司 克拉霉素多晶型物的制备方法和新的多晶型物ⅳ
CN1450903A (zh) * 2000-01-11 2003-10-22 特瓦制药工业有限公司 克拉霉素多晶型物的制备方法
CA2401571A1 (en) 2000-02-29 2001-09-07 Ilya Avrutov Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same

Also Published As

Publication number Publication date
AU2261901A (en) 2001-07-24
HRP20020572A2 (en) 2005-04-30
PT1280535E (pt) 2005-04-29
DK1280535T3 (da) 2005-04-04
KR20020071012A (ko) 2002-09-11
SI1280535T1 (enExample) 2005-08-31
DE60018119D1 (de) 2005-03-17
EP1280535A1 (en) 2003-02-05
CN1450903A (zh) 2003-10-22
EP1280535A4 (en) 2003-02-05
WO2001051059A1 (en) 2001-07-19
AU2001222619B8 (en) 2005-07-14
US6624292B2 (en) 2003-09-23
HUP0204252A3 (en) 2003-04-28
CA2397092A1 (en) 2001-07-19
HUP0204252A2 (hu) 2003-03-28
AU2001222619C1 (en) 2006-01-12
IS6463A (is) 2002-07-09
PL356645A1 (en) 2004-06-28
EP1280535B1 (en) 2005-02-09
ATE288758T1 (de) 2005-02-15
US20030216555A1 (en) 2003-11-20
AU2001222619B2 (en) 2005-04-28
ES2236023T3 (es) 2005-07-16
US20020028920A1 (en) 2002-03-07
ZA200205229B (en) 2003-06-30
BR0016992A (pt) 2002-12-31
DE60018119T2 (de) 2006-05-04
IL150698A0 (en) 2003-02-12
JP2003519661A (ja) 2003-06-24
US6987175B2 (en) 2006-01-17

Similar Documents

Publication Publication Date Title
RU2002118308A (ru) Способы получения полиморфных модификаций кларитромицина
BG101900A (en) Crystalline forms of 2-methyl-thieno-benzodiazepine and method for their preparation
CA2121435A1 (en) Aqueous pharmaceutical suspension and process for preparation thereof
IL150227A0 (en) Processes for preparing clarithromycin polymorphs and novel polymorph iv
RU2001118035A (ru) Этанолят азитромицина, процесс получения и содержащие его фармацевтические составы
RU94002474A (ru) Фармацевтический состав, содержащий нанокапсулы, и способ его получения
HU9201329D0 (en) The use of sulphonamides for medical purpose and process for the production of new sulphonamides
AR030056A1 (es) Proceso para la preparacion de citalopram purificado
EA200100955A1 (ru) 4-ОКСО-4,7-ДИГИДРОТИЕНО [2,3-b]ПИРИДИН-5-КАРБОКСАМИДЫ В КАЧЕСТВЕ АНТИВИРУСНЫХ СРЕДСТВ
RU2002105504A (ru) Твердый диспергирующий агент некристаллического цефуроксим-аксетила, способ его получения и композиция для его перорального введения
GB0117095D0 (en) "Process for the preparation of pure citalopram"
NO20006039D0 (no) Fremgangsmåte for fremstilling av 4-karboksyamino-2- substituert-1,2,3,4- tetrahydroquinolin
EP1676839A3 (fr) Nouvelle forme cristalline bêta du sel de tert-butylamine du perindopril, son procédé de préparation et les compositions pharmaceutiques qui la contiennent
CA2354880A1 (en) Method for the preparation of citalopram
HUP9900958A1 (hu) Új 2-fluor-3-de[(2,6-didezoxi-3-C-metil-3-O-metil-alfa-L-ribohexopiranozil)oxi]-6-O-metil-3-oxo-eritromicin-származékok, és előállításuk
CA2286511A1 (en) Novel macrolide derivatives
KR930016436A (ko) 4, 13-디옥사바이사이클로[8.2.1]트리데세논유도체와 그의 제조방법, 그의 제조를 위한 중간체 및 이화합물이 함유된 약학조성물
CA2510949A1 (en) Polymorph of ritonavir
EP0326386A3 (en) Isoquinolinones
US5912235A (en) 10, 13, 15-trioxatricyclo 9.2.1.1.9.6 !-pentadecan one derivatives, method for their production and pharmaceutical compositions containing them
MA27815A1 (fr) Forme cristalline alpha du ranelate de strontium, son procede de preparation, et les compositions pharmaceutiques qui la contiennent.
NZ509561A (en) Crystalline forms of osanetant
HRP20020344B1 (hr) Način priprave citaloprama
RU99100107A (ru) Производные дибензооксазепина и дибензодиоксепина и их применение в качестве противоопухолевых агентов
CA2195975A1 (en) An improved process for preparing side chain derivatives of cyclohexapeptidyl lipopeptides